What's New
News
Empower a Future Free of FTD with a Year-End Gift
For over 20 years, AFTD’s volunteers, supporters, and partners raised awareness, supported one another, educated healthcare professionals,…
Interactive Map Simplifies Search for Help on New AFTD “Find Support” Page
AFTD has just launched a new page designed to simplify your search for answers. We added an…
AFTD and ALLFTD Collaborate on Brain Donation Video
AFTD and ALLFTD have partnered to create a brief animated video that explains the brain donation process,…
Hope Rising Benefit Honors Dr. Bruce Miller, Raises $1.9 Million for AFTD’s Mission
The eighth annual AFTD Hope Rising Benefit, held April 4 at New York City’s Ziegfeld Ballroom, raised…
Balancing Safety and Autonomy When Persons Diagnosed Leave the Home
In recent days, national media outlets have reported on the disappearance of Edmond Bradley Solomon III, a…
AFTD Partners with ALS Association to Support Advancing Digital Tools
Although FTD and amyotrophic lateral sclerosis (ALS) have long been considered distinct disorders, experts now recognize that…
AFTD CEO Discusses Wendy Williams’s FTD Diagnosis
In an interview with The Daily Beast about Wendy Williams’s recent FTD diagnosis, AFTD CEO Susan L-J…
FDA Grants Breakthrough Therapy Designation to Experimental FTD Therapy
The U.S. Food and Drug Administration (FDA) has granted a “breakthrough therapy designation” to latozinemab, an experimental…
AFTD and ADDF Extend Treat FTD Fund Program Through 2035
AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF) have committed to extending the Treat FTD Fund program…
Open Hand Foundation Provides AFTD $600K for FTD Research
AFTD is pleased to announce that we have received a gift of $600,000 from the Open Hand…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)